Discover the impact of astatine-211 on bladder cancer · Learn more
Explore our scientific publications, clinical studies and advances in alpha-immunotherapy
This article reviews current and emerging therapeutic options for BCG-unresponsive non-muscle-invasive bladder cancer, with a particular focus on the potential of targeted alpha therapy compared with chemotherapy, immunotherapy, and gene therapy.
ClinicalTrials.gov ID NCT07260162 – Sponsor Institut Cancerologie de l'Ouest – ClinicalTrials.gov – NCT07260162
Watabe, T.; Naka, S.; Shirakami, Y.; Kaneda, K.; Murakami, M.; Toyoshima, A.; Cardinale, J.; Giesel, F.L. Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5. Seminars in Nuclear Medicine 2025;55(6):947-954. DOI: 10.1053/j.semnuclmed.2025.09.005
Watabe, T.; Mukai, K.; Naka, S.; Sasaki, H.; Kamiya, T.; Hayakawa, T.; Fukuhara, A.; Takano, T.; Shirakami, Y.; Ooe, K.; Shigeno, S.; Okamura, S.; Masumura, K.; Hida, E.; Haba, H.; Toyoshima, A.; Isohashi, K.; Shimomura, I.; Tomiyama, N. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of Nuclear Medicine 2025. – DOI: 10.2967/jnumed.125.270810
Rousseau, C.; Baumgartner, P.; Heymann, M.-F.; Taupin, M.; Geffroy, M.; Chatal, J.- F.; Gautier, G.; Allam, N.; Gaschet, J.; Eychenne, R.; Guérard, F.; Gestin, J.-F.; Varmenot, N.; Chérel, M. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [ 211 At]At-anti-CA-IX Antibody (ATO- 101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers 2025;17(7),1190. DOI: 10.3390/cancers17071190
ClinicalTrials.gov ID NCT04897763 – Sponsor Institut Cancerologie de l’Ouest – ClinicalTrials.gov – NCT04897763
ClinicalTrials.gov ID: NCT04897763 Sponsor: Institut de Cancérologie de l’Ouest (ICO) Collaborator: Atonco ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT04897763
ClinicalTrials.gov ID: NCT03670966 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03670966
ClinicalTrials.gov ID: NCT03128034 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03128034